Increase in incidence of lung cancer, especially in developing countries, is the key driver of the global lung cancer diagnostics market. Surge in awareness about the importance of early and accurate diagnosis of this cancer is expected to accelerate industry development.
Technological advancements in diagnostic technology such as development of non-invasive diagnostic methods and discovery of new biomarkers are anticipated to offer lucrative opportunities to market players.
However, high cost of diagnostic tests is a key lung cancer diagnostics market restraint. Availability of alternative diagnostic methods that are more accessible and cost-effective is also projected to hamper market progress. Manufacturers are investing significantly in R&D activities pertaining to new and improved diagnostic methods to increase their market share.
Lung cancer is a type of cancer that affects the cells lining the air passages. It is the leading cause of cancer deaths globally, accounting for over 1.7 million deaths each year. The two primary types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Early detection and treatment of lung cancer plays a crucial role in increasing the chances of survival. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy.
The choice of treatment depends on the type and stage of the cancer, as well as the patient's overall health. Various diagnostic tests and technologies are used to detect and diagnose lung cancer. Common diagnostic methods are chest X-ray, CT scan, PET scan, biopsy, and blood test.
| Attribute | Detail |
|---|---|
| Lung Cancer Diagnostics Market Drivers |
|
The rise in the incidence of lung cancer is a concerning public health issue that has been influenced by various factors over the past few decades. Primarily, the persistent use of tobacco products remains the leading cause, with smoking rates among both - men and women contributing significantly to the overall incidence.
As per estimates of the World Cancer Research Fund International, more than 2 million new lung cancer cases were reported in 2022. Lung cancer is the most commonly occurring cancer worldwide.
Furthermore, according to Lung Cancer Research Foundation, in 2023, approximately 654,620 people in the U.S. were diagnosed with lung cancer. It further states that people who have never smoked account for 20% of lung cancer diagnoses every year. An estimated 47,660 non-smokers were diagnosed with lung cancer in 2023.
Furthermore, exposure to air pollution, which includes hazardous chemicals and particulate matter, has been connected to an elevated risk of lung cancer, especially in metropolitan settings. An additional serious risk is the growing usage of radon gas in homes and workplaces, since extended exposure can cause cellular changes in lung tissue.
Another important issue is the aging population. As people live longer, their chance of developing lung cancer rises as a result of cumulative exposure to risk factors. Lung cancer detection has grown as a result of improvements in diagnostic methods, which enable earlier and more precise disease identification.
Taken as a whole, these components highlight the intricate interactions amongst environmental factors, lifestyle decisions, and demographic shifts that have resulted in an alarming rise in lung cancer incidence worldwide, thereby pushing the lung cancer diagnostics market.
The lung cancer diagnostics market is experiencing a significant growth due to technological advancements in various areas, including imaging, molecular diagnostics, and liquid biopsies. These advancements are driving the market growth by improving diagnostic accuracy, reducing invasive procedures, and enabling early detection and treatment of lung cancer.
For instance, in October, 2023, DELFI Diagnostics, Inc. announced the initial commercial introduction of FirstLook Lung. FirstLook is a blood test that offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT), with a negative predictive value (NPV) of 99.7%.
FirstLook Lung is based on the science of fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood.
Additionally, in December 2023, Biofidelity announced the commercial launch of its ASPYRE-Lung RUO reagent product. ASPYRE-Lung dramatically simplifies and accelerates the detection of genomic biomarkers, enabling localized testing at a fraction of the cost of current sequencing tests, with results available in days instead of weeks.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America’s lung cancer diagnostics market is driven by technological advancements such as robotic-assisted bronchoscopy and artificial intelligence in digital pathology is enhancing the accuracy and speed of lung cancer diagnosis.
For instance, In July 2021, The USA Health Mitchell Cancer Institute announced that it had started offering state-of-the-art lung cancer diagnosis through the implementation of advanced technologies, particularly the Auris Health Monarch robotic system.
This innovative system allows physicians to visualize and conduct biopsy of hard-to-reach lung nodules using a flexible endoscope, significantly enhancing diagnostic accuracy and efficiency. The Monarch system enables detailed visualization of the lungs, allowing for precise targeting of nodules that may be difficult to access using traditional methods.
The U.S. is dominating North America’s lung cancer diagnostics market due to several critical factors such as high prevalence of lung cancer in the U.S., driving demand for effective diagnostic solutions. Increased public awareness about lung cancer screening and ongoing government initiatives aimed at improving cancer care further contribute to the market's growth.
The global lung cancer diagnostics market share is fragmented with the presence of a number of players. Companies are engaging in partnerships and collaborations to gain a strong foothold in the market.
Abbott, Bio-Rad Laboratories, Inc., Siemens Healthcare, GE Healthcare, Amoy Diagnostics Co., Boditech Med, Inc., Danaher, F Hoffmann-La Roche, INOVIQ, MedGenome, Quest Diagnostics Incorporated, DiaSorin S.p.A., Oncocyte Corporation, QIAGEN, Thermo Fisher Scientific, Inc., NanoString Technologies, and Biodesix, are the prominent players in the lung cancer diagnostics market.
Key players have been profiled in the lung cancer diagnostics market research report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 15.1 Bn |
| Forecast Value in 2034 | More than US$ 34.8 Bn |
| CAGR | 7.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global lung cancer diagnostics market was valued at US$ 15.1 Bn in 2023
Lung cancer diagnostics business is projected to cross US$ 34.8 Bn by the end of 2034
The CAGR is anticipated to be 7.9% from 2024 to 2034
North America is expected to account for the largest share from 2024 to 2034
Abbott, Bio-Rad Laboratories, Inc., Siemens Healthcare, GE Healthcare, Amoy Diagnostics Co., Boditech Med, Inc., Danaher, F Hoffmann-La Roche, INOVIQ, MedGenome, Quest Diagnostics Incorporated, DiaSorin S.p.A., Oncocyte Corporation, QIAGEN, Thermo Fisher Scientific, Inc., NanoString Technologies, and Biodesix.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Lung Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
5.3. Lung Cancer Diagnostics Pricing Trends
5.4. Regulatory Landscape across Key Regions / Countries
5.5. PORTER’s Five Forces Analysis
5.6. PESTEL Analysis
5.7. Value Chain Analysis
5.8. Go-To Market Strategy for New Entrants
5.9. Key Purchase Metrics for End-users
5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
5.11. Benchmarking of the Products Offered by the Competitors
6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
6.3.1. Biopsy
6.3.1.1. Needle biopsy
6.3.1.2. Transbronchial biopsy
6.3.1.3. Thoracoscopic biopsy
6.3.1.4. Liquid Biopsy
6.3.1.4.1. Circulating Tumor Cells (CTCs)
6.3.1.4.2. Circulating Tumor DNA
6.3.1.4.3. Cell-Free RNA (cfRNA)
6.3.1.4.4. Exosomes
6.3.1.4.5. Proteomic Analysis
6.3.1.5. Others
6.3.2. Imaging Tests
6.3.2.1. Magnetic Resonance Imaging (MRI)
6.3.2.2. Computed Tomography (CT) Scan
6.3.2.3. Chest Ultrasound
6.3.2.4. Positron Emission Tomography (PET)
6.3.2.5. Other Imaging Tests
6.3.3. Molecular Testing
6.3.4. Others
6.4. Market Attractiveness By Diagnostic Test Type
7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product Type, 2020-2034
7.3.1. Instruments
7.3.2. Consumables
7.4. Market Attractiveness By Product Type
8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Cancer Type, 2020-2034
8.3.1. Non-small cell lung cancer (NSCLC)
8.3.2. Small cell lung cancer (SCLC)
8.4. Market Attractiveness By Cancer Type
9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Diagnostic & Imaging Centers
9.3.4. Cancer Research Institutes
9.4. Market Attractiveness By End-user
10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Lung Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
11.2.1. Biopsy
11.2.1.1. Needle biopsy
11.2.1.2. Transbronchial biopsy
11.2.1.3. Thoracoscopic biopsy
11.2.1.4. Liquid Biopsy
11.2.1.4.1. Circulating Tumor Cells (CTCs)
11.2.1.4.2. Circulating Tumor DNA
11.2.1.4.3. Cell-Free RNA (cfRNA)
11.2.1.4.4. Exosomes
11.2.1.4.5. Proteomic Analysis
11.2.1.5. Others
11.2.2. Imaging Tests
11.2.2.1. Magnetic Resonance Imaging (MRI)
11.2.2.2. Computed Tomography (CT) Scan
11.2.2.3. Chest Ultrasound
11.2.2.4. Positron Emission Tomography (PET)
11.2.2.5. Other Imaging Tests
11.2.3. Molecular Testing
11.2.4. Others
11.3. Market Value Forecast By Product Type, 2020-2034
11.3.1. Instruments
11.3.2. Consumables
11.4. Market Value Forecast By Cancer Type, 2020-2034
11.4.1. Non-small cell lung cancer (NSCLC)
11.4.2. Small cell lung cancer (SCLC)
11.5. Market Value Forecast By End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Diagnostic & Imaging Centers
11.5.4. Cancer Research Institutes
11.6. Market Value Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Diagnostic Test Type
11.7.2. By Product Type
11.7.3. By Cancer Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Lung Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
12.2.1. Biopsy
12.2.1.1. Needle biopsy
12.2.1.2. Transbronchial biopsy
12.2.1.3. Thoracoscopic biopsy
12.2.1.4. Liquid Biopsy
12.2.1.4.1. Circulating Tumor Cells (CTCs)
12.2.1.4.2. Circulating Tumor DNA
12.2.1.4.3. Cell-Free RNA (cfRNA)
12.2.1.4.4. Exosomes
12.2.1.4.5. Proteomic Analysis
12.2.1.5. Others
12.2.2. Imaging Tests
12.2.2.1. Magnetic Resonance Imaging (MRI)
12.2.2.2. Computed Tomography (CT) Scan
12.2.2.3. Chest Ultrasound
12.2.2.4. Positron Emission Tomography (PET)
12.2.2.5. Other Imaging Tests
12.2.3. Molecular Testing
12.2.4. Others
12.3. Market Value Forecast By Product Type, 2020-2034
12.3.1. Instruments
12.3.2. Consumables
12.4. Market Value Forecast By Cancer Type, 2020-2034
12.4.1. Non-small cell lung cancer (NSCLC)
12.4.2. Small cell lung cancer (SCLC)
12.5. Market Value Forecast By End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Diagnostic & Imaging Centers
12.5.4. Cancer Research Institutes
12.6. Market Value Forecast By Country / Sub-region, 2020-2034
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Diagnostic Test Type
12.7.2. By Product Type
12.7.3. By Cancer Type
12.7.4. By End-user
12.7.5. By Country / Sub-region
13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
13.2.1. Biopsy
13.2.1.1. Needle biopsy
13.2.1.2. Transbronchial biopsy
13.2.1.3. Thoracoscopic biopsy
13.2.1.4. Liquid Biopsy
13.2.1.4.1. Circulating Tumor Cells (CTCs)
13.2.1.4.2. Circulating Tumor DNA
13.2.1.4.3. Cell-Free RNA (cfRNA)
13.2.1.4.4. Exosomes
13.2.1.4.5. Proteomic Analysis
13.2.1.5. Others
13.2.2. Imaging Tests
13.2.2.1. Magnetic Resonance Imaging (MRI)
13.2.2.2. Computed Tomography (CT) Scan
13.2.2.3. Chest Ultrasound
13.2.2.4. Positron Emission Tomography (PET)
13.2.2.5. Other Imaging Tests
13.2.3. Molecular Testing
13.2.4. Others
13.3. Market Value Forecast By Product Type, 2020-2034
13.3.1. Instruments
13.3.2. Consumables
13.4. Market Value Forecast By Cancer Type, 2020-2034
13.4.1. Non-small cell lung cancer (NSCLC)
13.4.2. Small cell lung cancer (SCLC)
13.5. Market Value Forecast By End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Diagnostic & Imaging Centers
13.5.4. Cancer Research Institutes
13.6. Market Value Forecast By Country / Sub-region, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Diagnostic Test Type
13.7.2. By Product Type
13.7.3. By Cancer Type
13.7.4. By End-user
13.7.5. By Country / Sub-region
14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
14.2.1. Biopsy
14.2.1.1. Needle biopsy
14.2.1.2. Transbronchial biopsy
14.2.1.3. Thoracoscopic biopsy
14.2.1.4. Liquid Biopsy
14.2.1.4.1. Circulating Tumor Cells (CTCs)
14.2.1.4.2. Circulating Tumor DNA
14.2.1.4.3. Cell-Free RNA (cfRNA)
14.2.1.4.4. Exosomes
14.2.1.4.5. Proteomic Analysis
14.2.1.5. Others
14.2.2. Imaging Tests
14.2.2.1. Magnetic Resonance Imaging (MRI)
14.2.2.2. Computed Tomography (CT) Scan
14.2.2.3. Chest Ultrasound
14.2.2.4. Positron Emission Tomography (PET)
14.2.2.5. Other Imaging Tests
14.2.3. Molecular Testing
14.2.4. Others
14.3. Market Value Forecast By Product Type, 2020-2034
14.3.1. Instruments
14.3.2. Consumables
14.4. Market Value Forecast By Cancer Type, 2020-2034
14.4.1. Non-small cell lung cancer (NSCLC)
14.4.2. Small cell lung cancer (SCLC)
14.5. Market Value Forecast By End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Diagnostic & Imaging Centers
14.5.4. Cancer Research Institutes
14.6. Market Value Forecast By Country / Sub-region, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Diagnostic Test Type
14.7.2. By Product Type
14.7.3. By Cancer Type
14.7.4. By End-user
14.7.5. By Country / Sub-region
15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
15.2.1. Biopsy
15.2.1.1. Needle biopsy
15.2.1.2. Transbronchial biopsy
15.2.1.3. Thoracoscopic biopsy
15.2.1.4. Liquid Biopsy
15.2.1.4.1. Circulating Tumor Cells (CTCs)
15.2.1.4.2. Circulating Tumor DNA
15.2.1.4.3. Cell-Free RNA (cfRNA)
15.2.1.4.4. Exosomes
15.2.1.4.5. Proteomic Analysis
15.2.1.5. Others
15.2.2. Imaging Tests
15.2.2.1. Magnetic Resonance Imaging (MRI)
15.2.2.2. Computed Tomography (CT) Scan
15.2.2.3. Chest Ultrasound
15.2.2.4. Positron Emission Tomography (PET)
15.2.2.5. Other Imaging Tests
15.2.3. Molecular Testing
15.2.4. Others
15.3. Market Value Forecast By Product Type, 2020-2034
15.3.1. Instruments
15.3.2. Consumables
15.4. Market Value Forecast By Cancer Type, 2020-2034
15.4.1. Non-small cell lung cancer (NSCLC)
15.4.2. Small cell lung cancer (SCLC)
15.5. Market Value Forecast By End-user, 2020-2034
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Diagnostic & Imaging Centers
15.5.4. Cancer Research Institutes
15.6. Market Value Forecast By Country / Sub-region, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Diagnostic Test Type
15.7.2. By Product Type
15.7.3. By Cancer Type
15.7.4. By End-user
15.7.5. By Country / Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2023)
16.3. Company Profiles
16.3.1. Abbott
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. Siemens Healthcare
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. GE Healthcare
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. Amoy Diagnostics Co.
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. Boditech Med, Inc.
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Danaher
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. F. Hoffmann-La Roche
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. INOVIQ
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. MedGenome
16.3.9.1. Company Overview
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Business Strategies
16.3.9.5. Recent Developments
16.3.10. Quest Diagnostics Incorporated
16.3.10.1. Company Overview
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. Business Strategies
16.3.10.5. Recent Developments
16.3.11. DiaSorin S.p.A.
16.3.11.1. Company Overview
16.3.11.2. Financial Overview
16.3.11.3. Product Portfolio
16.3.11.4. Business Strategies
16.3.11.5. Recent Developments
16.3.12. Oncocyte Corporation
16.3.12.1. Company Overview
16.3.12.2. Financial Overview
16.3.12.3. Product Portfolio
16.3.12.4. Business Strategies
16.3.12.5. Recent Developments
16.3.13. QIAGEN
16.3.13.1. Company Overview
16.3.13.2. Financial Overview
16.3.13.3. Product Portfolio
16.3.13.4. Business Strategies
16.3.13.5. Recent Developments
16.3.14. Thermo Fisher Scientific, Inc.
16.3.14.1. Company Overview
16.3.14.2. Financial Overview
16.3.14.3. Product Portfolio
16.3.14.4. Business Strategies
16.3.14.5. Recent Developments
16.3.15. NanoString Technologies
16.3.15.1. Company Overview
16.3.15.2. Financial Overview
16.3.15.3. Product Portfolio
16.3.15.4. Business Strategies
16.3.15.5. Recent Developments
16.3.16. Biodesix
16.3.16.1. Company Overview
16.3.16.2. Financial Overview
16.3.16.3. Product Portfolio
16.3.16.4. Business Strategies
16.3.16.5. Recent Developments
16.3.17. Other Prominent Players
16.3.17.1. Company Overview
16.3.17.2. Financial Overview
16.3.17.3. Product Portfolio
16.3.17.4. Business Strategies
16.3.17.5. Recent Developments
List of Tables
Table 01: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
Table 02: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
Table 03: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
Table 04: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
Table 05: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type, 2020-2034
Table 06: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 07: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-users, 2020-2034
Table 08: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Region, 2020-2034
Table 09: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 10: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
Table 11: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
Table 12: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
Table 13: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
Table 14: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
Table 15: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 16: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
Table 19: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
Table 20: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
Table 21: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
Table 22: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
Table 23: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 24: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 25: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 26: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
Table 27: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
Table 28: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
Table 29: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
Table 30: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
Table 31: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 32: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 33: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 34: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
Table 35: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
Table 36: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
Table 37: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
Table 38: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
Table 39: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 40: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 41: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 42: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2020-2034
Table 43: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Biopsy, 2020-2034
Table 44: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Liquid Biopsy, 2020-2034
Table 45: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Imaging Tests, 2020-2034
Table 46: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Product Type , 2020-2034
Table 47: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by Cancer Type, 2020-2034
Table 48: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Lung Cancer Diagnostics Market Value (US$ Bn) Forecast, 2017-2031
Figure 02: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
Figure 03: Global Lung Cancer Diagnostics Market Share Analysis, by Diagnostic Test Type, 2023
Figure 04: Global Lung Cancer Diagnostics Market Share Analysis, by Diagnostic Test Type, 2034
Figure 05: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
Figure 06: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 07: Global Lung Cancer Diagnostics Market Share Analysis, by Product Type, 2023
Figure 08: Global Lung Cancer Diagnostics Market Share Analysis, by Product Type, 2034
Figure 09: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Type, 2024-2034
Figure 10: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type, 2023 and 2034
Figure 11: Global Lung Cancer Diagnostics Market Share Analysis, by Cancer Type, 2023
Figure 12: Global Lung Cancer Diagnostics Market Share Analysis, by Cancer Type, 2034
Figure 13: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 14: Global Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Lung Cancer Diagnostics Market Share Analysis, by End-user, 2023
Figure 16: Global Lung Cancer Diagnostics Market Share Analysis, by End-user, 2034
Figure 17: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 18: Global Lung Cancer Diagnostics Market Value Share Analysis, by Region, 2023 and 2034
Figure 19: Global Lung Cancer Diagnostics Market Share Analysis, by Region, 2023
Figure 20: Global Lung Cancer Diagnostics Market Share Analysis, by Region, 2034
Figure 21: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Region, 2023-2034
Figure 22: North America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 23: North America Lung Cancer Diagnostics Market Value Share Analysis, by Country, 2023 and 2034
Figure 24: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country, 2024-2034
Figure 25: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
Figure 26: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
Figure 27: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 28: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 29: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
Figure 30: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 31: North America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 32: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 34: Europe Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 35: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 36: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
Figure 37: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
Figure 38: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 39: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 40: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
Figure 41: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 42: Europe Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 43: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 45: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 46: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
Figure 48: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
Figure 49: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 50: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 51: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
Figure 52: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 53: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 54: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 55: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 56: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 58: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
Figure 59: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
Figure 60: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 61: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 62: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
Figure 63: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 64: Latin America Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 65: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 67: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 68: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 69: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Diagnostic Test Type, 2023 and 2034
Figure 70: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test Type, 2024-2034
Figure 71: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 72: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 73: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by Cancer Type , 2023 and 2034
Figure 74: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2024-2034
Figure 75: Middle East & Africa Lung Cancer Diagnostics Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 76: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Lung Cancer Diagnostics Market
